



This is a repository copy of *Novel bilayer mucoadhesive patches for delivery of clobetasol-17-propionate to the oral mucosa to treat oral lichen planus; an in vitro and in vivo evaluation.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/142089/>

Version: Accepted Version

Proceedings Paper:

Colley, H.E. orcid.org/0000-0003-0053-7468, Said, Z., Santocildes-Romero, M.E. et al. (7 more authors) (2018) Novel bilayer mucoadhesive patches for delivery of clobetasol-17-propionate to the oral mucosa to treat oral lichen planus; an in vitro and in vivo evaluation. In: Oral Surgery Oral Medicine Oral Pathology and Oral Radiology. Annual Meeting of the American Academy of Oral Medicine, 10-14 Apr 2018, San Antonio, TX, USA. Elsevier , e204-e204.

<https://doi.org/10.1016/j.oooo.2018.05.037>

Article available under the terms of the CC-BY-NC-ND licence
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Abstract

Novel bilayer mucoadhesive patches for delivery of clobetasol-17-propionate to the oral mucosa to treat oral lichen planus; an *in vitro* and *in vivo* evaluation

H.E Colley¹, Z Said¹, M.E. Santocildes-Romero¹, S.R. Baker¹, K. D'Apice¹, J. Hansen², L.Siim. Madsen², M.H. Thornhill^{1*}, P.V. Hatton¹ and C. Murdoch¹

¹School of Clinical Dentistry, The University of Sheffield, S10 2TA, Sheffield, UK.

²DermTreat ApS, Abildgaardsvej 174, 2830 Virum, Denmark.

*Presenter

Objectives:

Oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS) are chronic inflammatory conditions often characterised by erosive and/or painful oral lesions that have a considerable impact on quality of life. Current treatment often necessitates the use of steroids in the form of mouthwashes, creams or ointments but these are often ineffective due to inadequate drug contact times with the lesion. Here we evaluate the performance of novel bilayer mucoadhesive patches for uni-directional delivery of the steroid Clobetasol-17-propionate to the oral mucosa.

Methods:

Electrospun polymeric patches with an impermeable backing layer and mucoadhesive drug delivery layer were produced and characterised for their physical properties in the laboratory. The drug release profile, drug penetration and cytotoxicity of the system in delivering Clobetasol-17-propionate was evaluated using *ex-vivo* porcine oral mucosa and tissue engineered human oral mucosa. The ability of the system to deliver Clobetasol -17-propionate effectively into the oral mucosa, and local and systemic drug safety was then confirmed in *in vivo* mini-pig studies before evaluation of residence time and acceptability of the drug delivery system in a human volunteer study.

Results:

Clobetasol-17-propionate incorporated into the patches was released in a sustained manner in both tissue-engineered oral mucosa and *ex vivo* porcine mucosa. Clobetasol-17 propionate-loaded patches were further evaluated for residence time and drug release in an *in vivo* animal model and demonstrated prolonged adhesion and drug release at therapeutic-relevant doses and time points without local or systemic toxicity. Human studies confirmed long adhesion (residence) times and high levels of patient acceptability for use of the oral adhesive patches for treatment of oral mucosal disease.

Conclusions:

These data show that electrospun patches are adherent to mucosal tissue without causing tissue damage, and can successfully be loaded with and release Clobetasol and potentially other clinically active drugs into the oral mucosae in a sustained therapeutic manner. These patches hold great promise for improving the treatment of OLP, RAS and other immunoinflammatory oral diseases and are ready to enter phase 2 clinical trials.